WallStreetZenWallStreetZen

NASDAQ: BPTH
Bio Path Holdings Inc Stock

$0.87-0.03 (-3.33%)
Updated Oct 4, 2024
BPTH Price
$0.87
Fair Value Price
$1.96
Market Cap
$2.22M
52 Week Low
$0.86
52 Week High
$21.60
P/E
-0.05x
P/B
1.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.60M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.96
Operating Cash Flow
-$9M
Beta
0.68
Next Earnings
Nov 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BPTH Overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BPTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BPTH ($0.87) is undervalued by 55.66% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BPTH ($0.87) is significantly undervalued by 55.66% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BPTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BPTH due diligence checks available for Premium users.

Be the first to know about important BPTH news, forecast changes, insider trades & much more!

BPTH News

Valuation

BPTH fair value

Fair Value of BPTH stock based on Discounted Cash Flow (DCF)
Price
$0.87
Fair Value
$1.96
Undervalued by
55.71%
BPTH ($0.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BPTH ($0.87) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BPTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BPTH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.05x
Industry
-113.8x
Market
26.83x

BPTH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.72x
Industry
5.96x
BPTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BPTH's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
BPTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$5.1M
Liabilities
$3.8M
Debt to equity
2.96
BPTH's short-term assets ($5.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BPTH's short-term assets ($5.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BPTH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BPTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$0.0
Financing
$7.0M
BPTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BPTH vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BPTH$2.22M-3.22%-0.05x1.72x
GLMD$2.23M-11.21%-0.21x0.19x
ELAB$2.18M-18.18%-0.34x0.83x
SCPX$2.29M+0.55%-0.00x0.09x
ZVSA$2.31M-0.88%0.00x0.27x

Bio Path Holdings Stock FAQ

What is Bio Path Holdings's quote symbol?

(NASDAQ: BPTH) Bio Path Holdings trades on the NASDAQ under the ticker symbol BPTH. Bio Path Holdings stock quotes can also be displayed as NASDAQ: BPTH.

If you're new to stock investing, here's how to buy Bio Path Holdings stock.

What is the 52 week high and low for Bio Path Holdings (NASDAQ: BPTH)?

(NASDAQ: BPTH) Bio Path Holdings's 52-week high was $21.60, and its 52-week low was $0.86. It is currently -95.97% from its 52-week high and 1.4% from its 52-week low.

How much is Bio Path Holdings stock worth today?

(NASDAQ: BPTH) Bio Path Holdings currently has 2,552,190 outstanding shares. With Bio Path Holdings stock trading at $0.87 per share, the total value of Bio Path Holdings stock (market capitalization) is $2.22M.

Bio Path Holdings stock was originally listed at a price of $3,600.00 in Mar 4, 2008. If you had invested in Bio Path Holdings stock at $3,600.00, your return over the last 16 years would have been -99.98%, for an annualized return of -40.57% (not including any dividends or dividend reinvestments).

How much is Bio Path Holdings's stock price per share?

(NASDAQ: BPTH) Bio Path Holdings stock price per share is $0.87 today (as of Oct 4, 2024).

What is Bio Path Holdings's Market Cap?

(NASDAQ: BPTH) Bio Path Holdings's market cap is $2.22M, as of Oct 7, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bio Path Holdings's market cap is calculated by multiplying BPTH's current stock price of $0.87 by BPTH's total outstanding shares of 2,552,190.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.